Skip to main content
SpringerLink
Log in
Book cover

Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures pp 453–471Cite as

Management of Nausea and Vomiting in Cancer Patients

  • Chapter
  • First Online:

  • 1180 Accesses

Part of the book series: Cancer Growth and Progression ((CAGP,volume 13))

Abstract

Nausea and vomiting in patients with cancer may be due to the patient’s specific disease state or may be due to cancer treatment interventions such as chemotherapy, radiation therapy, opioids, or other medications. The main approach to the treatment of nausea and vomiting has been the use of antiemetic agents developed primarily for the prevention of chemotherapy-induced nausea and vomiting (CINV). Agents that were considered useful in the prevention of CINV have then been used for the treatment of established nausea and vomiting in cancer patients. Although there have been many clinical trials in the development of agents for the prevention of CINV [62, 64, 70], there have been very few clinical trials evaluating the efficacy of antiemetics in cancer patients with established nausea and vomiting [49, 82].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Aapro MS, Grunberg SM, Manikhas GM et al (2003) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449

    Article  Google Scholar 

  2. Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: A review of the literature. J Clin Psychiatr 62:22–31

    CAS  Google Scholar 

  3. Andrews PLR (1994) 5-HT3 receptor antagonists and antiemesis. In: King FD, Jones BJ, Sanger GJ (eds) s5-hydroxytryptamine-3 receptor antagonists. CRC, Boca Raton/London

    Google Scholar 

  4. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (1998) Prevention of chemotherapy and radiotherapy-induced emesis: results of Perugia consensus conference. Ann Oncol 9:811–819

    Article  Google Scholar 

  5. Arpornwirat W, Albert I, Hansen V et al (2009) Phase 2 trial results with the novel neurokini-1 receptor antagonist casopitan in combainat with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115:5807–5816

    Article  CAS  PubMed  Google Scholar 

  6. Berger, AM, Clark-Snow RA (2001) Adverse effects of treatment. In: Devita VT Jr, Helman S, Rosenberg E (eds) Principles and practice of oncology. Lippincott Williams and Wilkins, PA, USA, pp 2869–2880

    Google Scholar 

  7. Borison HL, McCarthy LE (1983) Neuropharmacology of chemotherapy-induced emesis. Drugs 25:8–17

    Article  CAS  PubMed  Google Scholar 

  8. Bubalo J, Seelig F, Karbowicz S, Maziarz RT (2001) Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:439–445

    Article  CAS  PubMed  Google Scholar 

  9. Bymaster FP, Calligaro D, Falcone J, Marsh RD, Moore NA, Tye NC et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96

    Article  CAS  PubMed  Google Scholar 

  10. Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW et al (2001) Potent antagonism of 5HT3 and 5HT6 receptors by olanzapine. Eur J Pharmacol 430:341–349

    Article  CAS  PubMed  Google Scholar 

  11. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767

    CAS  PubMed  Google Scholar 

  12. Cartmell AD, Ferguson S, Yanagihara R, Moiseyenko V, Van Marwijk Kooy R, Tripp F et al (2003) Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately of highly emetogenic chemotherapy by palonosetron, a potent 5HT3 receptor antagonist. In: Program/proceedings of the 39th annual meeting of the American society of clinical oncology, May 31–June 3, 2003. Chicago, IL. Abstract 3041

    Google Scholar 

  13. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME et al (2003) Establishing the dose of oral NK-1 antagonist aprepitant for chemotherapy induced nausea and vomiting. Cancer 97:2290–2300

    Article  CAS  PubMed  Google Scholar 

  14. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O’Brien M, Schellens JH et al (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835–842

    Article  CAS  PubMed  Google Scholar 

  15. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, Beurden V, Stoter G et al (1997) Patient perceptions of the side effects of chemotherapy: the influence of the 5-HT3 antagonists. Br J Cancer 76:1055–1061

    PubMed  Google Scholar 

  16. de Witt R, Herrstedt J, Rapoport BL, Carides AD, Casrides G, Elmer M et al (2003) Addition of the oral NK1 antagonist aprepitant to standard anti-emetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105–4111

    Article  CAS  Google Scholar 

  17. de Witt R, Herrstedt J, Rapoport BL, Carides AD, Guogwang-Ma J, Elmer M et al (2004) The oral NK-1 antagonist, aprepitant, given with standard anti-emetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled Phase III clinical trials. Eur J Cancer 40:403–410

    Google Scholar 

  18. deWit R, Schmitz PIM, Verweij J, de Boer-Dennert M, de Mulder PH, Planting AS et al (1996) Analysis of cumulative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 14:644–651

    CAS  Google Scholar 

  19. Diemunsch P, Grelot L (2000) Potential of substance P antagonists as anti-emetics. Drugs 60:533–546

    Article  CAS  PubMed  Google Scholar 

  20. Einhorn LH, Brames ML, Dreicer R et al (2007) Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cispaltin chemotherapy for germ cell cancer. Support Care Cancer 15:1293–1300

    Article  PubMed  Google Scholar 

  21. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482

    Article  CAS  PubMed  Google Scholar 

  22. Eisenberg P, MacKintosh FR, Ritch P Cornett PA, Macciocchi A (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330–337

    Article  CAS  PubMed  Google Scholar 

  23. Fabi A, Barduagni M, Lauro S, Portalone L, Mauri M, Marinis F et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156–161

    PubMed  Google Scholar 

  24. Fabi A, Ciccaresev M, Metro G et al (2008) Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. Support Care Cancer 16:1375–1380

    Article  PubMed  Google Scholar 

  25. Fasth KJ, Bergstrom M, Kilpatrick G (1997) Brain uptake and receptor binding of two C11 labeled selective high affinity NK-1 antagonists, GR203040 and GR 205171. J Labeled Comp Radiopharm 40:665–667

    Google Scholar 

  26. Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evakluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

    Article  CAS  PubMed  Google Scholar 

  27. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438–443

    CAS  PubMed  Google Scholar 

  28. Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577

    Article  CAS  PubMed  Google Scholar 

  29. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 17:2971–2994

    CAS  PubMed  Google Scholar 

  30. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM et al (1996) On the receiving and. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195

    CAS  PubMed  Google Scholar 

  31. Grunberg SM, Deuson R, Mavros P, Geling O, Hansen M, Cruciani G et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus reality. Cancer 100:2261–2268

    Article  PubMed  Google Scholar 

  32. Grunberg SM, Rolski J, Strausz J et al (2009) Efficacy and safety of casoitant mesylate, a neurokinin 1 (NK-1) receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomized, double-blind. placebo-controlled trial. Lancet Oncol 10:549–558

    Article  CAS  PubMed  Google Scholar 

  33. Guttuso T, Roscoe J, Griggs J (2003) Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 361:1703–1705

    Article  CAS  PubMed  Google Scholar 

  34. Hale AS (1997) Olanzapine. Br J Hosp Med 58:443–445

    Google Scholar 

  35. Herrstedt J, Apornwirat W, Shaharyar A et al (2009) Phase III of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27:5363–5369.

    Article  CAS  PubMed  Google Scholar 

  36. Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163–173

    Article  CAS  PubMed  Google Scholar 

  37. Hesketh PJ (2004) New treatment option for chemotherapy-induced nasusea and vomiting. Support Care Cancer 12:550–554

    PubMed  Google Scholar 

  38. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinksy ME et al (1999) Randomized Phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17:338–343

    CAS  PubMed  Google Scholar 

  39. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin-aprepitant protocol 052 study group. J Clin Oncol 21:4112–4119

    Article  CAS  PubMed  Google Scholar 

  40. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ et al (1994) A randomized double blind comparison of intravenous ondansetron and in combination with intravenous dexamethasone in the prevention of high dose cisplatin induced emesis. J Clin Oncol 12:596–600

    CAS  PubMed  Google Scholar 

  41. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109

    CAS  PubMed  Google Scholar 

  42. Hesketh PJ, Navari RM, Grote T, Gralla R, Hainsworth J, Kris M et al (1996) Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin induced emesis in patients with cancer. J Clin Oncol 14:2242–2249

    CAS  PubMed  Google Scholar 

  43. Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-HT3 receptor antagonists versus perchlorperazine for control of delayed emesis caused by doxrubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:756–772

    Article  CAS  Google Scholar 

  44. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 anti-emetics. Cancer 97:2880–2886

    Article  CAS  PubMed  Google Scholar 

  45. Ioanmidis JP, Hesketh PJ, Lau J (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-Analysis of randomized evidence. J Clin Oncol 18:3409–3422

    Google Scholar 

  46. Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliative Med 6:251–255

    Article  Google Scholar 

  47. Kimura E, Niimi E, Watanabe A (1996) Study on clinical effect of a continuous intravenous infusion of azasetron against the nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 23:477–481.

    CAS  PubMed  Google Scholar 

  48. Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong P et al (2000) Dexamethasone for the prophylaxis of radiation-induced Emesis: a national cancer institute of Canada clinical trials group study. J Clin Oncol 18:1960–1966

    CAS  PubMed  Google Scholar 

  49. Kris MG (2003) Why do we need another anti-emetic? J Clin Oncol 21:4077–4080

    Article  CAS  PubMed  Google Scholar 

  50. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of clinical Oncology guidelines for antiemtics in oncology: update. J Clin Oncol 24:2932–2934

    Article  CAS  PubMed  Google Scholar 

  51. Kris MG, Pendergrass KB, Navari RM, Grote TH, Nelson AM, Thomas V et al (1997) Prevention of acute emesis following high dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol 15:2135–2138

    CAS  PubMed  Google Scholar 

  52. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ (1997) Use of a NK1 receptor antagonist to prevent delayed emesis after cisplatin (letter). J Natl Cancer Inst 89:817–818

    Article  CAS  PubMed  Google Scholar 

  53. Lanciano R, Sherman DM, Michalski J. Preston AJ, Yocom K, Friedman, C (2001) The efficacy and safety of once- daily granisetron tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 19:763–772

    Article  CAS  PubMed  Google Scholar 

  54. Lasseter KC, Gambale J, Jin B et al (2007) Tolerability of foasaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834–840

    Article  CAS  PubMed  Google Scholar 

  55. Latreille J, Pater J, Johnston D. Laberge F, Stewart D, Rusthoven J et al (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174–1178

    CAS  PubMed  Google Scholar 

  56. Mantovani G, Maccio A, Alesandro B, Curreli L, Ghiani M, Proto E et al (1996) Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial. Cancer 77:941–948

    Article  CAS  PubMed  Google Scholar 

  57. Martin BR, Wiley JL (2004) Mechanism of action of cannabinoids; how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2:305–316

    CAS  PubMed  Google Scholar 

  58. Antiemetic Consensus Conference, Perugia, Italy (2004) Multi-national association, supportive care in cancer. Retrieved Nov 2009 from http://www.mascc.org

  59. Minami M, Endo T, Kikuchi K, Ihira E, Hirafuji M, Hamaue N et al (1998) Antiemetic effects of sendide, a peptide tachykinin NK-1 receptor antagonist, in the ferret. Eur J Pharmacol 363:49–55

    Article  CAS  PubMed  Google Scholar 

  60. Minami M, Endo T, Yokoda H, Ogawa M, Nemoto N, Hamaue M et al (2001) Effects of CP-99,994, a tachykinin NK-1 receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK-1 and 5-HT3 receptors. Eur J Pharmacol 428:215–220

    Article  CAS  PubMed  Google Scholar 

  61. Morrow GR, Hickok JT, Rosenthal SN (1995) Progress in reducing nausea and emesis: comparisons of ondansetron, granisetron, and tropisetron. Cancer 76:343–357

    Article  CAS  PubMed  Google Scholar 

  62. Navari RM (2003) Pathogenesis-based treatment of chemotherapy induced nausea and vomiting: two new agents. J Support Oncol 1:89–103

    Article  CAS  PubMed  Google Scholar 

  63. Navari RM (2004) Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 4(5) 715–724

    Article  CAS  PubMed  Google Scholar 

  64. Navari RM (2004) Inhibiting substance P pathway for prevention of chemotherapy-induced emesis: Preclinical data, clinical trials of neurokinin-1 receptor antagonists. Support Cancer Therapy 1:89–96

    Article  Google Scholar 

  65. Navari RM (2007) Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomting. Expert Opin Invest Drugs 16,1977–1985

    Article  CAS  Google Scholar 

  66. Navari RM (2007) Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 5:51–59

    CAS  PubMed  Google Scholar 

  67. Navari RM (2007) Review of updated antiemetic guidelines for chemotherapy-nnduced nausea and vomiting. Commun Oncol 4(1 Suppl) 3S–11S

    Google Scholar 

  68. Navari RM (2008) Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activties. Curr Opin Investig Drugs 9:774–785

    CAS  PubMed  Google Scholar 

  69. Navari RM (2009) Palonosetron: A second generation 5-hysroxytryptamin-3 receptor antagonist. Expert Opion Drug Metab Toxicol 5(12) 1–10

    Google Scholar 

  70. Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting. Focus on recent developments. Drugs 69:515–523

    Article  CAS  PubMed  Google Scholar 

  71. Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Vinson J, Johnson C et al (2005) A Phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 13:529–534

    Article  PubMed  Google Scholar 

  72. Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Vinson J, Johnson C et al (2007) A Phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15:1285–1291

    Article  PubMed  Google Scholar 

  73. Navari RM, Gandara D, Hesketh P, Hall S, Maillard J, Ritter H et al (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin induced emesis. J Clin Oncol 13:1242–1248

    CAS  PubMed  Google Scholar 

  74. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine receptor antagonist, for the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 12:2204–2210

    CAS  PubMed  Google Scholar 

  75. Navari RM, Koeller JM (2003) Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 37:1276–1286

    Article  CAS  PubMed  Google Scholar 

  76. Navari RM, Madajewicz S. Anderson N, Tchekmedyian NS, Whaley W, Garewal H et al (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large,multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408–241

    CAS  PubMed  Google Scholar 

  77. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J. Med 340:190–195

    Article  CAS  PubMed  Google Scholar 

  78. Clinical Practice Guidelines in Oncology: Antiemesis (2009) National comprehensive cancer network. Retrieved Nov 2009 from http://www.nccn.org

  79. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15:116–123

    CAS  PubMed  Google Scholar 

  80. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of post-chemotherapy nausea and vomiting on health related quality of life. Support Care Cancer 5:307–313

    Article  CAS  PubMed  Google Scholar 

  81. Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D et al (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 25:485–489

    Article  PubMed  Google Scholar 

  82. Passik SD, Lundberg J, Kirsh K, Theobald D, Donaghy K, Holtsclaw E et al (2002) A pilot exploration of the antiemetic activity of olanzapine (Zyprexa) for the relief of nausea in patients with advanced cancer and pain. J Pain and Symptom Manage 23:526–532

    Article  CAS  Google Scholar 

  83. Passik SD, Navari RM, Jung S, Nagy C, Vinson J, Kirsh K et al (2004) A phase I trail of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 22:383–388

    Article  CAS  PubMed  Google Scholar 

  84. Perez EA (1999) 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat 57:207–214

    Article  CAS  PubMed  Google Scholar 

  85. Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036–1043

    CAS  PubMed  Google Scholar 

  86. Perez EA, Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer RH et al (1997) Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin induced emesis. Support Care Cancer 5:31–37

    Article  CAS  PubMed  Google Scholar 

  87. Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 9:84–87

    Article  CAS  PubMed  Google Scholar 

  88. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al (2003) Addition of the neurokinin-1 receptor antagonist aprepitant to standard anti-emetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97:3090–3098

    Article  CAS  PubMed  Google Scholar 

  89. Roila F, Hesketh PJ, Herrstedt J (2006) Antiemetic subcommittee of the multinational association of supportive care in cancer. Ann Oncol 17:22–28

    Article  Google Scholar 

  90. Rudd JA, Naylor RJ (1994) Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 33:1607–1608

    Article  CAS  PubMed  Google Scholar 

  91. Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasoneversus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized comparative phase III trial. Lancer Oncol 10:115–124

    Article  CAS  Google Scholar 

  92. Sanger GJ (1992) The involvement of the 5-HT3 receptors in visceral function. In: Harmon M (ed) Central and peripheral 5-HT3 Receptors (pp. 207–255). Academic, London

    Google Scholar 

  93. Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an aprepitant regimen with a multi-day ondansetron regimen, both with dexamethasone, for the antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000–1006

    Article  CAS  PubMed  Google Scholar 

  94. Simpson K, Spencer CM, McClellan KJ (2000) Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 59:1297–1315

    Article  CAS  PubMed  Google Scholar 

  95. Slatin MD (2007) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting beyond prevention of acute emesis. J Support Oncol 5(3 Suppl): 1S–9S

    Google Scholar 

  96. Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J. Pain Symptom Manage 25:578–582

    Article  Google Scholar 

  97. Taguchi T, Tsukamoto F, Watanabe T (1999) Usefulness of ramosetron hydrochloride on nausea and vomting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 26:1163–1170

    CAS  PubMed  Google Scholar 

  98. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ et al (2000) The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phsophoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39:652–663

    Article  CAS  PubMed  Google Scholar 

  99. Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM et al (1996) Tachykinins NK-1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 35:1121–1129

    Article  CAS  PubMed  Google Scholar 

  100. Tavorath FD, Hesketh PJ (1996) Drug treatment of chemotherapy-induced delayed emesis. Drugs 52: 639–648

    Article  CAS  PubMed  Google Scholar 

  101. The Italian Group for Anti-emetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554–1559

    Article  Google Scholar 

  102. The Italian Group for Anti-emetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1–5

    Article  Google Scholar 

  103. The Italian Group for Anti-emetic Research (1998) Double blind dose finding study of four intravenous doses of dexamethasone in the prevention of cisplatin induced acute emesis. N Engl J Med 16:2937–2942

    Google Scholar 

  104. The Italian Group for Anti-emetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthrcyclines, carboplatin, or cyclophosphamide (published erratum appears in J Clin Oncol 22:2038). J Clin Oncol 22:725–729

    Article  CAS  Google Scholar 

  105. Van Belle S, Liechinitser M, Navari RM, Garin AM, Decramer ML, Riviere A et al (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-0869. Cancer 94:3032–3041

    Article  PubMed  Google Scholar 

  106. Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332

    Article  PubMed  CAS  Google Scholar 

  107. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830

    Article  CAS  PubMed  Google Scholar 

  108. Yates BJ, Grelot L, Kerman IA, Balaban CD, Jakus J, Miller AD (1994) Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol 207–255

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Indiana University School of Medicine, South Bend, IN, 46617, USA

    Rudolph M. Navari

  2. Walther Cancer Research Center, University of Notre Dame, South Bend, IN, 46617, USA

    Paula P. Province

  3. Sloan Kettering Cancer Center, Cornell University School of Medicine, New York, NY, USA

    Steven D. Passik

Authors
  1. Rudolph M. Navari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula P. Province
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven D. Passik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rudolph M. Navari .

Editor information

Editors and Affiliations

  1. Moores UCSD Cancer Center, 3855 Health Sciences Drive 0820, La Jolla, 92093-0820, California, USA

    Boris R. Minev

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Navari, R.M., Province, P.P., Passik, S.D. (2011). Management of Nausea and Vomiting in Cancer Patients. In: Minev, B. (eds) Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression, vol 13. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9704-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-9704-0_25

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-9703-3

  • Online ISBN: 978-90-481-9704-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation